Document is current
Any future updates will be listed below
-
Authors
Hamazaki, Kenya
Morikawa, Toru
Nezu, Mari
Oh, Koji
Nishio, Chihiro
Morimoto, Takeshi https://orcid.org/0000-0002-6844-739X
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 12 March 2025
First Online: 31 March 2025
Declarations:
:
: The Ethics Review Board of Kobe City Medical Center West Hospital (approval number: 23–017, 24–017) and Hyogo Medical University (approval number: 4770) approved this study.
: In place of a formal written consent, the opt-out consent method was displayed on the website of study hospital and allowed patients to refuse participation and/or publication.
: Dr. Hamazaki, Dr. Morikawa, Dr. Nezu, Dr. Oh, and Dr. Nishio report no competing interests. Dr. Morimoto reports lecturer's fees from Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Pfizer, Tsumura, and UCB; manuscript fee from Pfizer; advisory board for GlaxoSmithKline, Novartis, and Teijin.These pharmaceutical companies had no involvement in the study in any aspect.
Free to read: This content has been made available to all.
